Loading...
Nektar Therapeutics Community
NasdaqCM:NKTR Community- 2 Narratives written by author
- 0 Comments on narratives written by author
- 13 Fair Values set on narratives written by author
Community Investing Ideas
NKTR: Upcoming Phase 2b Data Readouts Will Drive Renewed Upside Momentum
Key Takeaways Advancing innovative therapies like REZPEG in large, underserved markets could drive substantial revenue growth and improve long-term financial performance. Strong cash reserves and accelerated regulatory paths enable operational stability, support pipeline expansion, and reduce near-term financial risks.Read more
0users have liked this narrative
0users have commented on this narrative
10users have followed this narrative
AN
US$93.86
30.0% undervalued intrinsic discount
AnalystConsensusTarget Fair Value
Revenue
-11% p.a.
Profit Margin
20.88%
Future PE
301.81x
Price in 2028
US$110.6
Immunotherapy Advances Will Serve Aging Demand Yet Face Regulatory Hurdles
Key Takeaways REZPEG is positioned to become a market leader in dermatology due to strong clinical data, expedited approval pathways, and potential broad patient reach. Nektar's solid financials and innovative technology platform offer undervalued growth potential, diversification, and appeal for strategic partnerships or acquisitions.Read more
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
US$120
45.3% undervalued intrinsic discount
AnalystHighTarget Fair Value
Revenue
-10% p.a.
Profit Margin
23.22%
Future PE
261.71x
Price in 2028
US$144.21
